Tag: Quviviq

Chronic insomnia disorder affects an estimated 10% of the adult population, leading many to seek medication [1.7.3]. For those prescribed the medication, a common question is: **what does Quviviq feel like?** This article explores the range of experiences.

According to the American Academy of Sleep Medicine, up to 30% of adults experience trouble sleeping, with 10% having severe insomnia. This has driven the development of new treatments, and the answer to 'What is the new drug to replace Ambien?' often points toward a different class of medications called orexin receptor antagonists. These newer sleep aids offer a different mechanism of action with distinct benefits and risks compared to Ambien and other older sedative-hypnotics.

According to the National Sleep Foundation, as many as 50% of older adults experience difficulty initiating or maintaining sleep. Historically, older sleep medications posed significant risks for this population, but a newer class of drugs has emerged. So, what is the new sleeping pill for the elderly? Newer medications called dual orexin receptor antagonists (DORAs) are offering a safer, more targeted approach to treating insomnia in older adults.

In 2020, 8.4% of adults reported taking sleep medication recently, with many relying on traditional options like Ambien [1.2.1]. The critical question for many remains: **Is there a sleep aid better than Ambien** available today? The answer is complex and depends on individual needs.

Chronic insomnia affects up to 12% of the adult population in Switzerland, with significant impacts on both physical and mental health. A modern treatment developed by Swiss biopharmaceutical company Idorsia, known as the 'Swiss sleep pill,' is QUVIVIQ (daridorexant), a dual orexin receptor antagonist (DORA) that works differently than traditional sedatives by targeting the brain's wakefulness system.